New psoriasis pill zasocitinib takes on deucravacitinib in Head-to-Head trial

NCT ID NCT06973291

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 trial tested whether the experimental drug zasocitinib works better than the approved drug deucravacitinib for moderate-to-severe plaque psoriasis. Over 600 participants took one tablet and one capsule daily for 16 weeks. The main goal was to see how many achieved completely clear skin (PASI-100) by week 16.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: zasocitinib (TAK-279) and deucravacitinib
What this could lead to: If zasocitinib works better than deucravacitinib, it could offer a new, more effective daily pill option for people with moderate-to-severe plaque psoriasis.
What could go wrong: This is a completed Phase 3 trial, but results are not yet public. Even if zasocitinib shows superiority, it may not work for everyone, and long-term safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

606 people

The number who actually took part.

Started

Jul 2025

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant has a diagnosis of chronic plaque psoriasis for \>=6 months prior to the screening visit. 2. Participant has stable plaque psoriasis, defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis, for \>=6 months before screening. 3. Participant has moderate-to-severe plaque psoriasis, as defined by a PASI score \>=12 and an sPGA score \>=3, at screening and Day 1. 4. Participant has plaque psoriasis covering \>=10 percent (%) of his or her total body surface area (BSA) at screening and Day 1. 5. Participant must be a candidate for phototherapy or systemic therapy. Exclusion Criteria: \- Target Disease-Related Exclusions: 1. Participant has evidence of nonplaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis). If a participant meets criteria for inclusion based on typical plaque psoriasis presentation, a limited amount of inverse psoriasis is not exclusionary. 2. Participant requires systemic treatment, other than nonsteroidal anti-inflammatory drugs, during the trial period for an immune related disease (for example, inflammatory bowel disease). 3. Participant has a history of excessive sun exposure, has used tanning booths within 4 weeks prior to Day 1, or is not willing to minimize natural and artificial sunlight exposure during the trial period. Use of sunscreen products and protective apparel is recommended when sun exposure cannot be avoided. 4. Participant has concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the trial assessments. Recent/Concurrent Infectious Disease Exclusions: 5. Tuberculosis (TB): 1. Participant has history of active TB infection, regardless of treatment status. 2. Participant has signs or symptoms of active TB (including, but not limited to, chronic fever, chronic productive cough, night sweats, or weight loss) as judged by the investigator. 3. Participant has evidence of latent TB infection (LTBI) as evidenced by a positive QuantiFERON-TB Gold (QFT) result OR 2 indeterminate QFT results, and participant does not have documentation of appropriate LTBI prophylaxis or is not able or not willing to initiate appropriate LTBI prophylaxis. 4. Participant has had any imaging trial during or 6 months prior to screening, including x-ray, chest computed tomography, Magnetic Resonance Imaging (MRI), or other chest imaging suggesting evidence of current active or a history of active TB. X-ray is required for all participants regardless of QFT results unless the participant has had normal chest imaging in the 6 months prior to screening. 6. Herpes infections: 1. Participant has active herpes virus infection, including herpes zoster or herpes simplex 1 and 2 (demonstrated on physical examination and/or medical history) at screening or Day 1. 2. Participant has history of serious herpetic infection that includes any episode of disseminated disease, multidermatomal herpes zoster, herpes encephalitis, ophthalmic herpes, or recurrent herpes zoster (defined as 2 episodes within 2 years). 7. Nonherpetic viral diseases: 1. Participant has presence of Hepatitis C Virus (HCV) antibody and a positive confirmatory test result for HCV ribonucleic Acid (RNA) (nucleic acid test or Polymerase Chain Reaction \[PCR\]). 2. Participant has presence of positive Hepatitis B Surface Antigen (HBsAg+), or indeterminate HBsAg, presence of HBV deoxyribonucleic Acid (DNA) (regardless of serology), or positive anti-hepatitis B core antibody without concurrent positive hepatitis B surface antibody (Hepatitis B Core Antibody \[HBcAb\] positive and Hepatitis B Surface Antibody \[HBsAb\] negative). 3. Participant has positive results for Human Immunodeficiency Virus (HIV) by serology, regardless of viral load. 8. Other infectious diseases: 1. Participant has a history of active infection or febrile illness within 7 days prior to Day 1, as assessed by the investigator. 2. Participant has history of symptoms suggestive of systemic or invasive infection within 30 days prior to Day 1. 3. Participant has history of bacterial, viral, or fungal infection that required hospitalization or treatment with intravenous antimicrobial therapy within 8 weeks prior to Day 1 or oral antimicrobial therapy within 30 days prior to Day 1. 4. Participant has a history of chronic or recurrent bacterial disease, including but not limited to chronic pyelonephritis or cystitis, chronic bronchitis/pneumonitis, osteomyelitis, or chronic skin ulcerations/infections or fungal infections (except superficial onychomycosis). 5. Participant has a history of an infected joint prosthesis, unless that prosthesis has been removed or replaced at least 60 days prior to Day 1. 6. Participant has a history of opportunistic infections (for example, Pneumocystis jirovecii pneumonia, histoplasmosis, coccidiomycosis). 7. Participant had a bacterial infection within 60 days prior to Day 1 for which he or she did not receive treatment. * Noninfectious Disorders Exclusions: 9. Participant has any clinically significant medical condition, evidence of an unstable clinical condition (for example, cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or immunologic), or vital signs/physical/laboratory/Electrocardiogram (ECG) abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of trial results. These include but are not limited to: 1. Participant has a history of known or suspected condition/illness that is consistent with compromised immunity, including but not limited to any identified congenital or acquired immunodeficiency, splenectomy. 2. Participant had a major surgery within 60 days prior to Day 1 or has a major surgery planned during the trial. 3. Participant has unstable, poorly controlled, or severe hypertension at screening, confirmed by 2 repeat assessments. 4. Participant has a history of Class III or IV congestive heart failure as defined by New York Heart Association criteria. 5. Participant has a history of cancer or lymphoproliferative disease, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix. 6. For participants with asthma, chronic obstructive pulmonary disease, or other pulmonary illnesses, participant has been hospitalized in the past 3 months, has ever required intubation for treatment, currently requires oral corticosteroids, or has required more than 1 course of oral corticosteroids within 6 months prior to Day 1. 7. Participant has any of the following cardiovascular disease history: * A new diagnosis of atrial fibrillation or an episode of atrial fibrillation with rapid ventricular response or other dysrhythmia, nonacute cardiac hospitalization (for example, pacemaker implantation), pulmonary embolism, or deep venous thrombosis within the past 6 months prior to screening. * Any history of cerebrovascular event, myocardial infarction, coronary stenting, or aorto-coronary bypass surgery. If, however, the investigator determines there are no suitable treatment alternatives available for the participant and it has been at least 6 months since the occurrence of any such event, the participant may enroll. 8. Participant has ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if he or she participated in the trial, in the opinion of the investigator. 9. Participant has significant/uncontrolled psychiatric illness, in the opinion of the investigator. 10. Participant has a history of clinically significant drug or alcohol abuse within 12 months prior to Day 1. * Prohibited Psoriasis Treatments Exclusions: For the below prohibited psoriasis treatments, the washout period prior to Day 1 is within the time frame indicated or 5 half-lives, whichever is longer, regardless of whether they are prescribed for psoriasis or another condition: 10. Participant has received any of the following biologics or biosimilar versions within the time frame indicated: 1. Antibodies to interleukin (IL)-12/-23, IL-17, or IL-23 (for example, ustekinumab, secukinumab, tildrakizumab, ixekizumab, or guselkumab) within 6 months prior to Day 1. 2. Tumor Necrosis Factor (TNF) inhibitor(s) (for example, etanercept, adalimumab, infliximab, or certolizumab) within 2 months prior to Day 1. 3. Agents that modulate integrin pathways to impact lymphocyte trafficking (for example, natalizumab) or agents that modulate B cells or T cells (for example, alemtuzumab, abatacept, or visilizumab) within 3 months prior to Day 1. 4. Rituximab or other immune cell-depleting therapy within 6 months prior to Day 1. 11. Participant has used medicated shampoo and/or body wash, including formulations containing but not limited to salicylic acid, corticosteroids, coal tar, vitamin D3 analogues, or other compounds used for the management of psoriasis within 2 weeks prior to Day 1. 12. Participant has used any topical medication that could affect psoriasis presentation (including but not limited to corticosteroids, salicylic acid, urea, alpha- or beta-hydroxy acids, anthralin, retinoids, vitamin D analogues \[such as calcipotriol\], methoxsalen, trimethylpsoralen, calcineurin inhibitors \[for example, tacrolimus\], tapinarof, roflumilast, Janus kinase (JAK) inhibitors, or tar) within 2 weeks prior to Day 1. 13. Participant has used any systemic nonbiologic treatment that could affect psoriasis presentation (including oral, intravenous, intramuscular, intra-articular, intrathecal, or intralesional corticosteroids; oral retinoids; immunosuppressive/immunomodulating medication; methotrexate; azathioprine; 6-thioguanidine; mercaptopurine; mycophenolate mofetil; hydroxyurea; cyclosporine; 1,25-dihydroxyvitamin D3 analogues; psoralens; sulfasalazine; fumaric acid derivatives; JAK inhibitors; apremilast) within 4 weeks prior to Day 1, or 5 half-lives, whichever is longer. Note: Intranasal corticosteroids, inhaled corticosteroids, and eye and ear drops containing corticosteroids are permitted. 14. Participant has used leflunomide within 6 months prior to Day 1. 15. Participant has received phototherapy (including Ultraviolet B \[UV B\], Psoralen plus Ultraviolet A \[PUVA\], tanning beds, therapeutic sunbathing) or excimer laser within 4 weeks prior to Day 1. 16. Participant has used botanical preparations (for example, herbal supplements or traditional medicines, including traditional Chinese medicines derived from plants, minerals, or animals) intended to treat psoriasis or other immunological diseases within 4 weeks prior to Day 1. 17. Participant is currently being treated with oral antihistamines for any reason, with the exception of oral antihistamines that are administered at a stable dose for at least 4 weeks prior to Day 1. Note: Additional treatment with oral antihistamines may be permitted after discussion with the medical monitor. 18. Participant has any previous exposure to zasocitinib (also known as TAK-279 or NDI 034858) or other Tyrosine Kinase 2 (TYK2) inhibitors (including deucravacitinib), or participated in any trial that included a TYK2 inhibitor (for example, deucravacitinib, VTX958, GLPG3667, et cetera), unless participant has documentation of posttrial unblinding that confirms the participant did not receive a TYK2 inhibitor. \- Other Prohibited Concomitant Medications Exclusions: For the below prohibited concomitant medications, where applicable, the washout period prior to Day 1 is within the time frame indicated or 5 half-lives, whichever is longer. 19. Participant has received lithium, antimalarials, or intramuscular gold therapy within 4 weeks prior to Day 1. 20. Participant is currently being treated with strong or moderate Cytochrome P450 3A4 (CYP3A4) inhibitors (such as itraconazole) or strong or moderate CYP3A4 inducers (such as rifampin, carbamazepine, or phenytoin), or has received strong or moderate CYP3A4 inhibitors or strong or moderate CYP3A4 inducers within 4 weeks or 5 half-lives of the inducer or inhibitor, whichever is longer, prior to Day 1, or is anticipated to require treatment with strong or moderate CYP3A4 inducers or inhibitors during the trial period. Note: This includes consumption of food or beverages containing grapefruit and/or Seville oranges within 1 week of Day 1. Participants must be counseled to avoid food or beverages containing grapefruit and/or Seville oranges for the duration of the trial. 21. Participant has received any live-attenuated vaccine within 60 days prior to Day 1 or plans to receive a live-attenuated vaccine during the trial and up to 4 weeks after the last trial intervention administration. Note: Non-live-attenuated vaccines or boosters for Coronavirus Disease 2019 (COVID-19) or influenza are permitted during the trial. 22. Participant received an investigational antibody or biologic therapy within 6 months prior to Day 1. 23. Participant received an investigational oral therapy within 3 months prior to Day 1. 24. Participant is currently receiving a nonbiological trial intervention or device or has received one within 4 weeks prior to Day 1. 25. Participant is currently enrolled in a clinical trial or anticipates enrollment in a clinical trial during the course of the trial. \- Laboratory/Physical Exclusions: 26. Participant has any of the following laboratory values at the screening visit: 1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values greater than (˃)3\*upper limit of normal (ULN). 2. Total Bilirubin (Tbili) (unconjugated and/or conjugated) ˃1.5\*ULN. 3. Hemoglobin less than (\<) 9.0 grams per deciliter (g/dL) (\<90.0 grams per liter \[g/L\]). 4. Absolute white blood cell (WBC) count \<3.0\*109/liters (L) (\<3000 per cubic millimeter \[/mm3\]). 5. Absolute neutrophil count of \<1.0\*109/L (\<1000/mm3). 6. Absolute lymphocytes count of \<0.5\*109/L (\<500/mm3). 7. Platelet count \<100\*109/L (\<100,000/mm3). 8. Thyroid-stimulating hormone outside the normal reference range AND free T4 or T3 outside the normal reference range. 9. Estimated creatinine clearance \<45 milliliters per minute (mL/min) based on the Cockcroft-Gault calculation. 10. Creatine phosphokinase (CPK) \> ULN. CPK may be repeated once; if repeat value is Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or lower (or \<=2.5\*ULN) and no higher than the initial value, participant remains eligible. Investigators should assess the participant for modulating factors, including concomitant medications or vigorous exercise, that may affect CPK levels. 27. Participant has any other significant laboratory abnormalities that, in the opinion of the investigator, might place the participant at unacceptable risk for participation in this trial. 28. Participant does not tolerate venipuncture or inability to be venipunctured. \- Allergies and Adverse Drug Reactions Exclusions: 29. Participant has history of significant drug allergy (such as anaphylaxis). 30. Participant has a known or suspected allergy to zasocitinib or deucravacitinib or any of their components.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

Advanced Clinical Research Institute

Tampa, Florida, 33607-6429, United States
Aesthetic dermatology clinic of prof. J. Kisis

Riga, LV-1003, Latvia
Alliance Clinical Trials

Waterloo, Ontario, N2J 1C4, Canada
Ambulatorium Sp. z o.o. | Elblag, Poland

Elblag, Warmian-Masurian Voivodeship, 20-573, Poland
Apex Clinical Research Center, LLC - Canton

Canton, Ohio, 44718, United States
Apex Clinical Research Center, LLC - Mayfield Heights

Mayfield Heights, Ohio, 44124-4005, United States
Arlington Dermatology

Rolling Meadows, Illinois, 60008-3811, United States
Arlington Research Center

Arlington, Texas, 76011-3800, United States
Beacon Dermatology - Probity

Calgary, Alberta, T3E 0B2, Canada
Bellaire Dermatology Associates

Bellaire, Texas, 77401-3505, United States
Bexley Dermatology Research - Probity - PPDS

Bexley, Ohio, 43209, United States
Brunswick Dermatology Centre - Probity

Fredericton, New Brunswick, E3B 1G9, Canada
Burke Pharmaceutical Research

Hot Springs, Arkansas, 71913-6475, United States
CCR Ostrava s.r.o.

Ostrava, Moravian-Silesian Region, 702 00, Czechia
CLINTRIAL s.r.o.

Prague, 100 00, Czechia
Central Connecticut Dermatology, PLLC

Cromwell, Connecticut, 06416, United States
Centre Hospitalier Le Mans

Le Mans, Sarthe, 72037, France
Centre Hospitalier Universitaire de Saint Etienne

Saint-Etienne, 42270, France
Centre de Recherche Dermatologique du Quebec Metropolitain

Québec, G1V 4X7, Canada
Centrum Badan Klinicznych Pi-house Sp. Z O. O.

Gdansk, Pomeranian Voivodeship, 80-546, Poland
Centrum Columbus

Wroclaw, Lower Silesian Voivodeship, 51-503, Poland
Centrum Terapii Współczesnej J.M. Jasnorzewska S.K.A.

Lodz, Łódź Voivodeship, 90-338, Poland
Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.p

Wroclaw, Lower Silesian Voivodeship, 50-566, Poland
ClinicMed Daniluk, Nowak Spolka Komandytowa

Bialystok, Podlaskie Voivodeship, 15-879, Poland
Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States
Dawes Fretzin Clinical Research Group, LLC

Indianapolis, Indiana, 46250, United States
Dermatrials Research

Hamilton, Ontario, L8N 1Y2, Canada
Dermedic Jacek Zdybski

Ostrowiec Swietokrzyski, Lower Silesian Voivodeship, 27-400, Poland
DermoDent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski, s.c.

Osielsko, Kuyavian-Pomeranian Voivodeship, 86-031, Poland
Dermoklinika-Centrum Medyczne s.c

Lodz, Łódź Voivodeship, 90-436, Poland
Dermskin s.r.o

Olomouc, Olomouc Region, 779 00, Czechia
Diagnostic Consultative Center Sveti Georgi EOOD

Haskovo, 6300, Bulgaria
Diagnostic Consultative Center XXVIII - Sofia - EOOD

Sofia, Sofia-Grad, 1592, Bulgaria
Diagnostic and Consulting Center Aleksandrovska EOOD

Sofia, Sofia-Grad, 1431, Bulgaria
Direct Helpers Research Center

Hialeah, Florida, 33012, United States
Dr Chih-Ho Hong Medical Inc

Surrey, British Columbia, V3V 6A7, Canada
ETG Warszawa - PPDS

Warsaw, Masovian Voivodeship, 02-677, Poland
ETYKA Osrodek Badan Klinicznych

Olsztyn, 10-117, Poland
Endeavor Health Clinical Trials

Skokie, Illinois, 60077, United States
Enverus Medical Research - Probity

Surrey, British Columbia, V3V 0C6, Canada
First OC Dermatology Research Inc.

Fountain Valley, California, 92708, United States
Fukuoka University Hospital

Fukuoka, Fukuoka, 814-0180, Japan
Goodlettsville Dermatology Research

Goodlettsville, Tennessee, 37072, United States
Health Center 4, Center of Diagnostics

Riga, 1003, Latvia
Health Center 4, Clinic of Dermatology

Riga, 1013, Latvia
Henry Ford Health System

Detroit, Michigan, 48202, United States
Hino Dermatology Clinic

Fukutsu-shi, Fukuoka, 811-3217, Japan
Hopital Charles Nicolle-1 Rue de Germont

Rouen, 76031, France
Houston Center for Clinical Research, LLC

Sugar Land, Texas, 77479-1001, United States
Investigational Product department

Sapporo, Hokkaido, 060-0063, Japan
Investigational Product department Dermatology and Ophthalmology Kume Clinic

Sakai-shi, Osaka, 593-8324, Japan
JCHO Tokyo Yamate Medical Center

Shinjuku-ku, Tokyo-to, 169-0073, Japan
JDR Dermatology Research, LLC

Las Vegas, Nevada, 89145, United States
JR Sapporo Hospital

Sapporo, Hokkaido, 060-0033, Japan
Jichi Medical University Hospital

Shimotsuke-shi, Tochigi, 329-0498, Japan
Johnson Dermatology

Fort Smith, Arkansas, 72916-6103, United States
Klinika Ambroziak Dermatologia

Warsaw, Masovian Voivodeship, 02-953, Poland
Klinika Reuma Park Sp. z o.o. sp. k. | Centrum Medyczne Reuma Park

Warsaw, Masovian Voivodeship, 02-665, Poland
Krakowskie Centrum Medyczne Sp. z o.o.

Krakow, Lesser Poland Voivodeship, 31-501, Poland
Lawrence J Green, MD LLC

Rockville, Maryland, 20850, United States
Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity

Hamilton, Ontario, L8L 3C3, Canada
Luxderm Specjalistyczny Gabinet Dermatologiczny Dorota Krasowska

Lublin, Lublin Voivodeship, 20-573, Poland
Lynderm Research Inc - Probity

Markham, Ontario, L3P 1X3, Canada
MICS Centrum Medyczne Warszawa

Warsaw, Masovian Voivodeship, 00-874, Poland
Markowitz Medical PLLC dba OptiSkin Medical

New York, New York, 10128, United States
Medical Center Asklepii OOD

Dupnitsa, Kyustendil, 2600, Bulgaria
Medical Center Hera EOOD-Sofia

Sofia, Sofia-Grad, 1510, Bulgaria
Medical Center Medconsult Pleven - Lovech Branch

Lovech, 5500, Bulgaria
Medical Center Unimed EOOD-Sevlievo

Sevlievo, Gabrovo, 5400, Bulgaria
Medical Centre Femiclinic EOOD

Sofia, Dianabad District, 1113, Bulgaria
Medical Corporation Jitai-kai Tachikawa Dermatology Clinic

Tachikawa-shi, Tokyo, 190-0023, Japan
Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia

Sofia, Sofia-Grad, 1606, Bulgaria
Multiprofile Hospital For Active Treatment Dr Tota Venkova

Gabrovo, 5300, Bulgaria
NZOZ Holsamed-Oddział Libero

Katowice, 229 40-600, Poland
Nagoya City University Hospital

Nagoya, Aichi-ken, 467-8602, Japan
Nemocnice AGEL Novy Jicin a.s

Nový Jičín, Moravian-Silesian Region, 741 01, Czechia
Nippon Life Hospital

Osaka, Osaka, 550-0006, Japan
North Bay Dermatology Center - Probity

North Bay, Ontario, P1B 3Z7, Canada
Office of Mireille Ruer-Mulard, MD

Martigues, Paca, 13500, France
Ohyama Dermatology Clinic

Kumamoto, 861-4101, Japan
Outpatient Clinic Adoria

Riga, LV-1011, Latvia
Praglandia s.r.o.

Prague, 150 00, Czechia
Pratia Brno s.r.o. - PRATIA - PPDS

Brno, South Moravian, 602 00, Czechia
Pratia Pardubice

Pardubice, 53002, Czechia
Prof. MUDr. Petr Arenberger, DrSc. - CRC - PPDS

Prague, 110 00, Czechia
Reveal Research Institute

Dallas, Texas, 75235, United States
Riga 1st Hospital

Riga, LV-1001, Latvia
Royalderm Agnieszka Nawrocka

Warsaw, 02 962, Poland
San Antonio

San Antonio, Texas, 78213-2250, United States
San Marcus Research Clinic Inc

Miami Lakes, Florida, 33014, United States
Seikoukai Omi Medical Center

Kusatsu-shi, Shiga, 525-8585, Japan
Semigallia

Kuldīga, LV-3301, Latvia
Shirasaki Dermatology Clinic

Takaoka-shi, Toyama, 933-0871, Japan
Siena Medical Research Corporation

Montreal, Quebec, H3Z 2S6, Canada
Skin Centre for Dermatology

Peterborough, Ontario, K9J 5K2, Canada
Skinsense Medical Research

Saskatoon, Saskatchewan, S7K 2C1, Canada
St. Luke's International Hospital

Chuo-ku, Tokyo, 104-8560, Japan
Texas Dermatology and Laser Specialists-San Antonio

San Antonio, Texas, 78218-3128, United States
The Centre For Dermatology

Richmond Hill, Ontario, L4B 1A5, Canada
The Centre for Clinical Trials Inc.

Oakville, Ontario, L6J 7W5, Canada
The University of Texas Health Science Center at Houston (UTHSC-H)

Bellaire, Texas, 77401, United States
Tokyo Medical University Hospital

Shinjuku-Ku, Tokyo, 160-0023, Japan
Twoja Przychodnia - Szczecinskie Centrum Medyczne

Szczecin, 71-500, Poland
UNISON Clinical Trials (Shahram Jacobs md inc.)

Sherman Oaks, California, 91403, United States
UPMC Department of Dermatology

Pittsburgh, Pennsylvania, 15213-3403, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27516, United States
Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie

Rzeszów, Podkarpackie Voivodeship, 35-055, Poland
VIDA Dermatology - Probity

Edmonton, Alberta, T6H 4J8, Canada
Veseliba un estetika Ltd.

Riga, LV-1009, Latvia
Wiseman Dermatology Research Inc.

Winnipeg, Manitoba, R3M 3Z4, Canada
XLR8 Medical Research

Windsor, Ontario, N8T1E6, Canada
Yale University School of Medicine

New Haven, Connecticut, 06511, United States
Zenith Research, Inc.

Beverly Hills, California, 90212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.